The EXPRESS study including tumor samples with a broad range of demographic and clinicopathological characteristics reported an overall 52% of PD-L1 TPS ≥ 1% and 22% of PD-L1 TPS ≥ 50% in patients with advanced NSCLC.12 The corresponding values in the current study were 51.8% of PD-L1 TPS ≥ 1% and 21.5% of PD-L1 TPS ≥ 50%. Here, CD274 is linked to neoplasm.